Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/1/2021 | $8.00 | Buy | Ascendiant Capital Markets |
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that Alzamend's board of directors approved a one-for-ten reverse stock split of Alzamend's common stock ("Common Stock") that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on July 16, 2024. Beginning with the opening of trading on July 16, 2024, the Company's Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Co
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
424B5 - Alzamend Neuro, Inc. (0001677077) (Filer)
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen
Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), announced that Adtech Pharma, Inc. ("Adtech"), has appointed Jodi Brichan, to its Board of Directors. Ms. Brichan was a member of the board of directors of the Company until August 13, 2021. In June of 2021, the Company entered a securities purchase agreement (the "Agreement") with Adtech that granted the Company the right to acquire up to 40% of the current equity in Adtech, an innovative biotechnology company, for $3 million. The right to appoint Ms. Brichan was provided for in the Agreement. The investment in Adtech was made through Digital Power Lending, LLC, a wholly owned subsidiary of the Company. J
Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company ("AGH," or the "Company"), announced the results of the Company's 2021 Annual Meeting of Stockholders (the "Meeting"), which was held today, August 13, 2021, at 9:00 a.m. PT, and at which time the seven proposals voted upon, as set forth in the Company's Definitive Proxy Statement dated June 7, 2021 (the "Proxy Statement"), were approved by the stockholders. At the Meeting, the stockholders voted upon and approved the following proposals as described in the Proxy Statement: Election of the eight (8) director nominees named in the Proxy Statement to hold office until the next annual meeting of stockholders; Ratificatio
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
5 - Alzamend Neuro, Inc. (0001677077) (Issuer)
BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the third quarter ended September 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Third quarter 2022 highlights include: Total assets of $610.9 million as of September 30, 2022; Positive working capital of $25.7 million as of September 30, 2022; Cash and cash equivalents of $10.1 million as of September 30, 2022; Revenue from cryptocurrency mining of $3.9 million, compared to $0.3 million in the prior third fiscal quarter; Revenue from the Company's majority owned subsidiary, The Singing Machine Company, Inc. (NASDAQ:MICS)
BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the second quarter ended June 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Second quarter 2022 highlights include: Total assets of $596.3 million as of June 30, 2022; Positive working capital of $51.4 million as of June 30, 2022; Cash and cash equivalents of $24.1 million as of June 30, 2022; Revenue from cryptocurrency mining of $4.0 million, compared to $0.3 million in the prior second fiscal quarter; Revenue from hotel operations of $4.6 million, compared to $0 in the prior second fiscal quarter; Revenue from lendi
The Company Grows Revenue by 120% to $52 Million and Ends the Year with $490 Million in Assets BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") today announced its financial results for the year ended December 31, 2021 contained within its Form 10‑K filed with the Securities and Exchange Commission. Year ended December 31, 2021 highlights: Revenue of $52.4 million, an increase of 120% from $23.9 million in the prior fiscal year; Revenue from lending and trading activities of $16.9 million due to the allocation of capital to Digital Power Lending, LLC ("DP Lending"); Revenue from trading activities during the year ended December 31, 2021
Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committee Identified dose is unlikely to require lithium therapeutic drug monitoring Data will guide upcoming "Lithium in Brain" Phase II clinical trials in partnership with Massachusetts General Hospital, which were announced in August 2024 Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announc
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has received formal written notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq") that Alzamend has demonstrated compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"), which requires a minimum stockholders' equity of $2,500,000. As previously reported, on September 26, 2023, Alzamen
Fireside conversation to take place on October 17, 2024, at 1:30 PM ET Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that CEO Stephan Jackman will participate in a fireside chat at the upcoming Maxim Group Virtual Healthcare Conference. The conversation will take place with a senior member of Maxim Group's biotech research team on Thursday, October 17, 2024, at 1:30 pm ET. Mr. Jackman looks forward to providing an overview of Alzamen